Ranexa (Ranolazine) is applied in the management of chronic stable angina in adults. It is generally indicated as an add-on therapy for patients whose symptoms are persistent despite optimal initial management or whose individual clinical profile suggests the use of an alternative agent. It is commonly used to help manage the recurring chest pressure and discomfort associated with chronic stable angina.

This medication supports symptomatic relief across several key domains, including easing the overall symptom load related to the frequency of anginal episodes and supporting an improvement in functional capacity and tolerance for physical activity. The core benefit involves easing symptoms that interfere with daily comfort and restrict physical activity.

“Ranexa assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Chronic Chest Discomfort

Ranexa is primarily relevant for patients dealing with persistent symptoms of chronic stable angina, particularly those related to exertional pain and recurrent anginal episodes. It contributes to easing discomfort during symptomatic periods, especially when added to an existing treatment plan.

Regulatory References

1. European Medicines Agency therapeutic overview

Who Can and Cannot Use Ranexa 375 mg?

The population eligibility for Ranexa (ranolazine) is strictly defined by regulatory authorities and centers on age, organ function, and existing conditions. It is indicated for use only in adults aged 18 years and older; use is not recommended in the pediatric population as safety and efficacy have not been established.

Contraindications and Restrictions

Ranexa is contraindicated and must not be used by specific patient groups, primarily due to risks associated with drug exposure:

• Patients with moderate or severe hepatic impairment (including liver cirrhosis).
• Patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Use requires special care and cautious dose titration in several populations where increased drug exposure or underlying cardiac instability is a concern. These include the elderly, patients with low body weight (less than or equal to 60 kg), and individuals with mild hepatic or mild to moderate renal impairment. Caution is also required for patients with moderate to severe Congestive Heart Failure (NYHA Class III–IV).

Regarding reproductive status, Ranexa is not recommended for use during pregnancy, and official guidance for breastfeeding mothers advises weighing potential benefits against risks due to limited data.

Ranexa (Ranolazine) interactions are formally documented based on the drug's influence over key metabolic enzymes and transport proteins, resulting in specific prohibitions and restrictions outlined in official regulatory documents.

Prohibited Combinations

Co-administration is strictly contraindicated with both strong CYP3A Inhibitors (e.g., ketoconazole, certain HIV protease inhibitors) and strong CYP3A Inducers (e.g., rifampin, St. John’s Wort). These prohibitions are based on the documented risk of severely altering Ranolazine plasma exposure. Additionally, certain QTc prolonging antiarrhythmics (e.g., quinidine, dofetilide) are contraindicated due to the potential for additive pharmacodynamic effects on the heart’s electrical activity.

Exposure and Substrate Restrictions

Ranolazine is documented to increase the systemic plasma exposure of co-administered drugs that are substrates for the CYP2D6 enzyme and the P-glycoprotein transporter. This includes the cardiac glycoside Digoxin and certain Statins (e.g., simvastatin). The official label notes that co-administration with moderate CYP3A inhibitors (e.g., diltiazem, verapamil) also results in increased Ranolazine concentrations. Grapefruit or grapefruit juice must be avoided, as this is formally documented to increase Ranolazine plasma levels. Due to exacerbated interaction risks, the severity is heightened in patients with moderate or severe hepatic impairment, a patient population formally classified as a contraindication in the regulatory label.

The drug's primary action is to engage mechanisms that regulate processes within the heart muscle cells, contributing to altered electrical and functional properties of the myocardial cell. It influences physiological response by targeting two key domains: ion current modulation and myocardial metabolism.

Cardiac Ion Current Modulation

This domain covers the drug's primary action as a selective inhibitor of the late sodium current (INaL) in the heart muscle. By limiting this persistent Na^+ flow, the drug modifies the early molecular steps that shape cellular physiological outcomes, directly influencing the balance of ions necessary for myocardial cellular activity.

Modulation of Myocardial Relaxation

This section explains the mechanistic cascade where the reduction of intracellular sodium indirectly modulates calcium homeostasis. This effect leads to a lower accumulation of Ca^2+ within the heart muscle, influencing the activity within targeted pathways and modulating the heart muscle's ability to relax during the diastolic phase.

Modification of Energy Utilization

The drug also acts within domains involving enzyme-mediated signaling to produce a secondary metabolic effect. This mechanism involves modifying energy substrate use to favor glucose over fatty acids, which modifies the ratio of oxygen consumed per ATP generated and alters myocardial performance during periods of elevated energy requirement.

Official Administration Guidelines for Ranexa (Ranolazine)

Ranexa 375 mg is a prolonged-release tablet intended solely for oral administration. Its usage is governed by specific dosing schedules and administration rules.

---

Dosing and Titration Protocol

The recommended initial dose of the extended-release tablet is 375 mg twice daily (BID) in Europe or 500 mg twice daily (BID) in the United States. The dose is designed to be gradually adjusted (titrated) based on the patient's status, typically increasing after two to four weeks of therapy. The maximum recommended daily dose differs by region: 750 mg twice daily in Europe or 1000 mg twice daily in the US.

Dosing Parameter	European Guidance	US Guidance
Initial Dose	375 mg twice daily (BID)	500 mg twice daily (BID)
Maximum Dose	750 mg twice daily (BID)	1000 mg twice daily (BID)
Titration Interval	Generally every 2–4 weeks	Based on clinical symptoms

---

Administration Rules and Constraints

The prolonged-release tablets must be swallowed whole; they should not be crushed, broken, or chewed to preserve the controlled-release mechanism. The medication may be taken with or without food. If a dose is missed, instructions are to skip the missed dose and take the next dose at the regularly scheduled time; a double dose should not be taken.

Specific dosing limitations apply when the medicine is used concurrently with certain other agents. For instance, the maximum dose of Ranexa should be limited to 500 mg twice daily when used with moderate CYP3A inhibitors, such as diltiazem or verapamil.

Research evidence / Overview of studies for Ranexa 375 mg

---

Clinical Studies for Chronic Stable Angina

The core evidence for Ranolazine was established through several short-term, double-blind Randomized Controlled Trials (RCTs). These studies examined Ranolazine when studied in combination with existing standard anti-anginal medications for chronic stable angina. The research examined adults who already had chronic stable angina and were often taking other standard heart medications, such as beta-blockers or calcium channel blockers. These controlled studies compared the findings observed in the patients taking Ranolazine against those taking a placebo (a non-active pill).

Research examined these trials as a comparison against a placebo pill, which served as the non-active control. The main outcomes studies monitored were related to two key areas: the patient's capacity to perform physical activity and their subjective experience of chest discomfort. Findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level, as well as patient-reported outcomes describing perceived physical discomfort.

Evaluation of Exercise Capacity and Functional Outcomes

Research explored how Ranolazine was studied for its association with physical capacity by using standardized treadmill stress tests. These studies monitored physiological strain or stress during periods of heightened symptom activity. Researchers focused on measurements such as the total exercise duration and the time until the onset of angina symptoms. Research describes measurements of physical capacity during exercise testing in the studied groups and in the placebo groups.

Long-Term Follow-up and Data on Hard Clinical Events

The primary symptomatic assessment trials used for research purposes were limited to short durations, generally spanning a few weeks up to three months. However, long-term effects are not fully established by the same rigorous, controlled methods used for the short-term symptomatic assessment. Furthermore, the evidence related to major, hard clinical outcomes—such as cardiovascular death or myocardial infarction (heart attack)—is limited and uncertain in patients with chronic stable angina. Research has explored these outcomes, but existing studies provide limited insight into long-term outcomes related to these rare but serious events.

Research in Specific Patient Groups

Ranolazine was evaluated in research contexts involving patients who have other pre-existing health issues. Studies observed patterns related to these patient groups, including those with diabetes mellitus and certain classifications of chronic heart failure. While these groups were included in the broader clinical trials, subgroup findings are uncertain and data for certain groups remain limited. Results apply only to the populations studied.

Common questions about Ranexa 375 mg (FAQ)

Q: What are the serious warnings or precautions for Ranexa?

Regulatory documents include a Warning and Precaution regarding QT interval prolongation. This is a change in the heart's electrical activity that is a risk for potentially serious heart rhythms. Special care and close monitoring, including dose adjustment, are noted as being necessary for populations that may experience increased drug exposure, such as the elderly, individuals with low body weight, and those with mild liver or kidney impairment.

Q: What is the starting dose of Ranexa?

The recommended initial dose documented in official product information varies based on the regulatory region. The starting strength is specified in regulatory documents as a lower strength twice-daily tablet, with the exact milligram amount depending on the prescribing region (e.g., Europe vs. the United States). The dose is typically adjusted over time based on the patient's clinical status.

Q: What is the mechanism of action of Ranexa (how does it work)?

Ranexa is classified as an anti-anginal agent that works by targeting specific processes within the heart muscle cells. Its primary action is a selective inhibition of the late sodium current within the heart. By limiting this persistent sodium flow, the drug contributes to modifying the electrical and functional properties of the heart muscle, providing an overall anti-ischemic effect.

Q: What kind of studies were done for Ranexa, and did they show it prevents heart attacks?

The evidence supporting the use of Ranexa comes primarily from short-term, randomized controlled trials (RCTs) that studied the drug in combination with existing anti-anginal medications. These studies mainly monitored patient outcomes related to exercise capacity and a reduction in chest pain symptoms. Official research documents indicate that the evidence related to major, hard clinical events—such as heart attack or cardiovascular death—is limited and uncertain in patients with chronic stable angina.

Q: How long does it take for Ranexa to start working for angina?

Studies and official product information indicate that the concentration of ranolazine in the blood generally peaks between 2 and 5 hours after the extended-release tablet is administered. Clinical trials observed patterns related to improvements in measures like exercise duration at both the lowest and highest expected drug concentrations during the day.

Q: What is the difference between Ranolazine and a beta-blocker?

Official information states that Ranolazine is chemically distinct from older anti-anginal drugs like beta-blockers. Ranolazine is a selective inhibitor of the late sodium current that provides anti-ischemic effects without relying on reducing heart rate or blood pressure, which is how beta-blockers typically work. It can often be used alongside beta-blockers for managing chronic angina.

How to Store and Dispose of Ranexa 375 mg?

The storage and disposal of Ranexa (ranolazine) 375 mg extended-release tablets are governed by official regulatory instructions to ensure product stability and safety.

Official Storage Requirements

Requirement	Specific Instruction
Temperature	Store at room temperature, generally not exceeding 30 C in some markets.
Environmental Protection	Keep the tablets away from excess heat and moisture. Do not freeze the medicine.
Container Integrity	The medicine must be kept in its original container, which must be securely tightly closed at all times.
Child Safety	All medication must be stored out of the sight and reach of children.

Disposal of Unused Tablets

Official labeling requires that any unused or expired Ranexa tablets be disposed of according to local regulations. Consult a pharmacist or local waste management services for guidance on proper collection and disposal to prevent environmental contamination.